|
市場調查報告書
非典型抗精神病藥：生命週期管理及未來動向
Atypical Antipsychotics: Life-Cycle Management and Future Trends
|
本報告已在2011年12月21日停止出版。
目前估計有150億美元規模的抗精神病藥市場隨著非專利藥品的抬頭，預計在2015年之前將大幅萎縮。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：Massachusetts State），針對非典型抗精神病藥的動向進行調查分析，並系統整理調查結果後出版報告書 "Atypical Antipsychotics: Life-Cycle Management and Future Trends" 。
本報告書內容包括：目前非典型抗精神病藥市場概要及主要產品、市場領導企業、銷售金額、至2015年為止的銷售金額動向及新一代抗精神病藥、未來的生存策略等。內容綱要摘記如下：
實施概要
抗精神病藥市場概要
主要產品：非典型抗精神病藥
- Johnson & Johnson的Risperdal
- Eli Lilly的Zyprexa
- AstraZeneca的Seroquel
- Pfizer的Geodon
- Bristol-Myers Squibb及大塚製藥股份有限公司的Abilify
非典型抗精神病藥的生命週期管理
新治療方式的競爭：目前投入市場的非典型抗精神病藥未來將如何發展？
- Johnson & Johnson的Paliperidone
- Organon的Asenapine
- Solvay/Wyeth/Lundbeck的Bifeprunox
- 已投入市場中的抗精神病藥 對 新一代的抗精神病藥
2015年之前非典型抗精神病藥的市場發展預測
表
- 目前投入市場的非典型抗精神病藥
- 抗精神病藥的市場占有率：2000年至2005年
- 非典型抗精神病藥市場的主要專利到期
- 根據各種指標進行的非典型抗精神病藥比較
- 適用症狀別、地區別第1、第2受歡迎的非典型抗精神病藥
- 已投入市場中的抗精神病藥：新處方及臨床研究中未經承認的病症
- 未來看好的「新一代」非典型抗精神病藥
圖
- 非典型抗精神病藥銷售金額擴大：2000年至2005年
- 目前主要的抗精神病藥 對 新一代抗精神病藥的市場占有率預測：2010年至2015年
- 地區別抗精神病藥銷售金額預測：2010年及2015年
Abstract
"Risperidone' s U.S. patent will expire in 2007, changing the landscape for all
atypical antipsychotics as cost becomes a prescribing and reimbursement
factor. Competitors will best preserve revenue streams by gaining approval for
new indications. Bipolar depression is among the most promising additional
labels that companies are pursuing."- Lulu Pickering, Ph.D., Program
Manager
Introduction
The $15 billion antipsychotics market will be hard hit by generics of nearly
all the most frequently prescribed atypicals and by a dearth of breakthrough
therapies in the pipeline. Overall market decline will be signifi cant by
2015, but current market leaders are staking out new territories to defend
their franchises.
Get the Answers You Need to Shape Your Strategy
At present, because all marketed atypicals (except clozapine) are expensive,
cost is not generally a factor in a physician' s choice of agent. That will
change when the patent for branded risperidone expires. What factors do
physicians consider in prescribing? How will prescribing change when
lower-cost generics are available? How will payers respond to availability of
generic risperidone?
Pending genericization and a less than robust pipeline threaten the historic
growth of the antipsychotics marketplace. What kind of sales are
antipsychotics likely to generate in 2010? In 2015? What is the outlook for
emerging atypicals?
A variety of tactics are available to manufacturers of current and emerging
atypicals. What specifi c strategies are companies pursuing? Will today' s
prominent players continue to lead the marketplace?
Scope
- The current market: Key players, atypical antipsychotics, current
market leaders, indications, sales, major markets.
- Market outlook: Sales trends through 2015, key players,
"new-generation" atypicals,genericization, reimbursement issues, declining
markets.
- Survival strategies: Life-cycle management, line extensions, new
indications and patient populations.
Mentioned in This Report-Companies
- Astellas
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- Johnson & Johnson
- Lundbeck
- Novartis
- Organon
- Otsuka
- Pfi zer
- Solvay
- Wyeth
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview of Antipsychotics Marketplace
- Key Players- Atypical Antipsychotics
- Johnson & Johnson' s Risperdal
- Eli Lilly' s Zyprexa
- AstraZeneca' s Seroquel
- Pfizer' s Geodon
- Bristol-Myers Squibb' s and Otsuka' s Abilify
- Life-Cycle Management of Atypical Antipsychotics
- Competition from New Therapies: How Will Currently Marketed Atypicals
Fare?
- Johnson & Johnson' s Paliperidone
- Organon' s Asenapine
- Solvay/Wyeth/Lundbeck' s Bifeprunox
- Marketed Atypicals vs
- Market Outlook for Atypical Antipsychotics Through 2015
Tables
- 1. Currently Marketed Atypical Antipsychotics
- 2. Market Shares of Antipsychotics, 2000-2005
- 3. Key Patent Expiries in the Antipsychotics Marketplace
- 4. Comparison of Atypical Antipsychotics on Various Parameters
- 5. First and Second Most-Preferred Atypical Antipsychotics, by Indication
and Region, 2005
- 6. Marketed Atypical Antipsychotics: New Formulations and Nonapproved
Indications Under Clinical Investigation
- 7. Promising "New-Generation" Atypical Antipsychotics
Figures
- 1. Atypical Antipsychotics, Sales Growth, 2000-2005
- 2. Projected Market Share of Current Leading Atypicals vs 2010-2015
- 3. Projected Regional Antipsychotics Sales, 2010 and 2015
|
